1 (tie), A Lim Kim, Hyo Joo Kim, Cheyenne Knight, Lydia Ko and Nelly Korda, 1.00%. 6 (tie), Celine Boutier, Ayaka Furue, Jin Young Ko and Patty Tavatanakit, .67%. 10, Hannah Green, .60%. 1 (tie), ...
Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its fourth quarter and full year 2024 ...
No, Bernie Sanders and Elizabeth Warren aren’t top recipients of pharmaceutical industry donations
A quirk in the website OpenSecrets has given RFK Jr. a chance to misleadingly portray Sen. Bernie Sanders as receiving big ...
A Feature on M&A, VC investment licensing and partnerships focusing on novel targets in autoimmune diseases. The global ...
The Phase 1b/2a study will assess the safety of CNP-103 in adults (aged 18-35) and pediatrics (aged 12-17) who have Stage III or newly diagnosed (within the last 6 months) T1D as well as C-peptide ...
In February 2024, the government slashed GST (Goods and Services Tax) from three major cancer drugs: Trastuzumab Deruxtecan, ...
ETH Zurich and HSG launch Manufacturing Alliance to strengthen Switzerland as an industrial location
Roche, Novartis, Johnson & Johnson Innovative Medicine, Takeda, SHL Medical, Nestlé, Lindt & Sprüngli, Givaudan, Schneider Electric, Schindler, Endress+Hauser Flowtec, VAT Group and SFS Group. They ...
As we move forward, the BMC remains dedicated to its mission of elevating industry-wide excellence in biospecimen management, raising the bar for data integrity and quality, enabling the future of ...
Neurocrine Biosciences Inc. (NASDAQ:NBIX), a $15.4 billion biopharmaceutical company, has reported a recent insider transaction. According to a filing with the Securities and Exchange Commission, ...
The global enzyme replacement therapy market size was valued at USD 10.12 billion in 2024 and is projected to grow from USD 11.35 billion in 2025 to reach USD 21.29 billion by 2033, exhibiting a CAGR ...
Neurocrine Biosciences Inc. (NASDAQ:NBIX), a $15.4 billion biopharmaceutical company that has delivered an impressive 11.7% return year-to-date, reported a stock sale by Chief Financial Officer Matt ...
Several therapeutic advances have been achieved over the past two decades for inflammatory bowel disease (IBD). The expanding ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback